Alkermes plc Appoints Joshua Reed as CFO to Drive Growth and Innovation

Alkermes Appoints Joshua Reed as Chief Financial Officer: A Strategic Move for Growth

Alkermes plc, a biopharmaceutical company specializing in innovative treatments for neurological disorders, announces the appointment of Joshua Reed as its new Chief Financial Officer, effective September 15, 2025. Reed, who brings over 30 years of financial leadership experience, will report directly to CEO Richard Pops and become a key member of the management committee. His extensive background in the biotechnology and pharmaceutical sectors positions him well to contribute to Alkermes' long-term objectives, especially as the company seeks to expand its commercial operations and enhance its product pipeline.

Reed's professional journey includes significant roles at notable companies, including his recent tenure as CFO at Omega Therapeutics and Aldeyra Therapeutics. His prior experience at Bristol Myers Squibb as Vice President and Head of Finance Operations for the U.S. and Puerto Rico further enriches his qualifications. Reed's academic credentials, which include a Bachelor of Science in Finance from Rutgers University and an MBA from the University of Michigan's Ross School of Business, complement his professional expertise. Richard Pops expresses enthusiasm about Reed's arrival, highlighting that his financial acumen and strategic insight will be essential as Alkermes navigates its current phase of growth and transformation.

The timing of Reed's appointment is crucial for Alkermes, which is poised to drive advancements in its diverse portfolio of treatments targeting alcohol and opioid dependence, schizophrenia, and bipolar I disorder. As the company continues to innovate and expand its operations, Reed's leadership in finance will play a pivotal role in ensuring that Alkermes maintains its competitive edge in the biopharmaceutical industry. This strategic move demonstrates Alkermes' commitment to enhancing its financial framework to support ongoing development and future initiatives.

In addition to Reed's appointment, Alkermes remains focused on its mission to develop effective therapies for patients with complex neurological conditions. The company, headquartered in Ireland, operates additional facilities in Massachusetts and Ohio, reflecting its commitment to maintaining a robust manufacturing and operational presence. As Alkermes strives for long-term growth and value creation for its stakeholders, Reed’s leadership is expected to be instrumental in navigating the company through the evolving landscape of biopharmaceutical innovation.